(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 September 2017 (14.09.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/156103 A1

(51) International Patent Classification:
A61K 31/57 (2006.01) *A61K 31/575* (2006.01)
A61K 31/56 (2006.01) *A61K 31/58* (2006.01)

(21) International Application Number:
PCT/US2017/021325

(22) International Filing Date:
8 March 2017 (08.03.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/305,279	8 March 2016 (08.03.2016)	US
62/355,174	27 June 2016 (27.06.2016)	US
62/355,669	28 June 2016 (28.06.2016)	US
62/360,762	11 July 2016 (11.07.2016)	US
62/360,758	11 July 2016 (11.07.2016)	US

(71) Applicant: **SAGE THERAPEUTICS, INC.** [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventor; and
(71) Applicant : **COLQUHOUN, Helen** [US/US]; 23 Regis Road, Arlington, MA 02474 (US).

(72) Inventor: **KANES, Stephen, Jay**; 125 Guernsey Rd, Swartmore, PA 19081 (US).

(74) Agent: **MCCARTY, Catherine, M.**; LANDO & ANASTASI, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

(57) Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).




FIG. 1A

WO 2017/156103 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*